AHS makes another retinal drug available through RAPID
By Gillian Slade on August 17, 2017.
Medicine Hat News One more drug will be covered by the province for the treatment of retinal conditions such as macular degeneration. Eylea will be covered effective Aug. 1 in addition to Lucentis and Avastin, which were announced in 2015 under the Retina Anti-Vascular Endothelial Growth Factor Program for Intraocular Disease (RAPID), in partnership with the Retina Society of Alberta. The RAPID program and prescription drugs are provided at no cost, so patients have no out-of-pocket co-payments for their treatments, said a press release from Alberta Health. 5-4
